Virological Failure in Two Patients with HIV-1 RNA Viral Loads >1,000,000 copies/ml Initiated on Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate
Free accessCase reportFirst published online February, 2016
Virological Failure in Two Patients with HIV-1 RNA Viral Loads >1,000,000 copies/ml Initiated on Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate
Very high baseline HIV-1 RNA viral loads require potent and robust antiretroviral regimens to achieve virological suppression. The coformulated single tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) is recommended by the US Department of Health and Human Services for the treatment of HIV-1 in treatment-naive adults and adolescents regardless of baseline CD4+ T-cell count and viral load. We report two cases of HIV-infected, treatment-naive patients, with baseline HIV-1 RNA viral loads >1,000,000 copies/ml who were initiated on the single tablet regimen EVG/COBI/FTC/TDF, but failed to attain viral load suppression and developed resistance to the components of EVG/ COBI/FTC/TDF.
References
1.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Updated 8 April 2015. Accessed 20 June 2015.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
2.
SaxP.E., DeJesusE., MillsA.Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3 trial, analysis of results after 48 weeks.Lancet2012; 379: 2439–2448.
3.
DeJesusE., RockstrohJ.K., HenryK.Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3, non-inferiority trial.Lancet2012; 379: 2429–2438.
4.
ElionR., SquiresK., BlochM.Subgroup analyses of 144-week efficacy and safety of elvitegravir/cobicistat/ emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF).ICAAC. 5–9 September 2014, Washington, DC, USA. Abstract H-644.
5.
WensingA.M., CalvezV., GunthardH.F.Special contribution: 2014 update of the drug resistance mutations in HIV-1.Top Antiv Med2014; 22: 642–650.
6.
StephanC., HillA., SawyerY.Impact of baseline HIV-1 RNA levels on highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials.HIV Med2013; 14: 284–292.
7.
SantoroM.M., ArmeniaD., AlteriC.Impact of pretherapy viral load on virological response to modern first-line HAART.Antivir Ther2013; 18: 867–876.
8.
TaiwoB., ZhengL., GallienS.Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).AIDS2011; 25: 2113–2122.
9.
RaffF., BabikerA.G., RichertL.Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.Lancet2014; 384: 1942–1951.
10.
WhiteK.L., KulkarniR., McCollD.J.Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.Antivir Ther2015; 20: 317–327.
11.
KulkarniR., AbramM.E., McCollD.J.Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir + ritonavir + emtricitabine/tenofovir DF in antiretroviral-naive patients.HIV Clin Trials2014; 15: 218–230.
12.
LiuT.F., ShaferR.W.Web resources for HIV type 1 genotypic-resistance test interpretation.Clin Infect Dis2006; 42: 1608–1618.
13.
BlancoJ.L., VargheseV., RheeS.Y.HIV-1 integrase inhibitor resistance and its clinical implications.J Infect Dis2011; 203: 1204–1214.
14.
GerettiA.M., ArmeniaD., Ceccherini-SilbersteinF.Emerging patterns and implications of HIV-1 integrase inhibitor resistance.Curr Opin Infect Dis2012; 25: 677–686.
15.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate). Prescribing information. Gilead Sciences Inc.Foster City, CA, USA.
16.
RamanathanS., MathiasA., WeiX.Pharmacokinetics of once-daily boosted-elvitegravir when administered in combination with acid reducing agents.J Acquir Immune Defic Syndr2013; 64: 45–50.
17.
KimD., ZiebellR., SaduvalaN.Trend in transmitted HIV-1 ARV drug resistance-associated mutations: 10 HIV surveillance areas, US, 2007–2010.20th Conference on Retroviruses and Opportunistic Infections. 3–6 March 2013, Atlanta, GA, USA. Abstract 149.
